All the news Showing 10 of 46 articles from: Nucleotide Ns5B polymerase inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir taken before or after liver transplant reduces hepatitis C recurrence Liz Highleyman / 08 November 2013 An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly two-thirds of patients, while the same regimen led to early viral clearance in three-quarters of those ... Sofosbuvir + ribavirin produces sustained response in 76% of genotype 1 HIV/HCV co-infected people Liz Highleyman / 08 November 2013 An interferon-free regimen of sofosbuvir plus ribavirin taken for 24 weeks cured hepatitis C infection in three quarters of previously untreated HIV-positive people co-infected with hepatitis C virus (HCV) genotype 1, while ... Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial Liz Highleyman / 06 November 2013 A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response (SVR12) in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course ... Interferon-free simeprevir + sofosbuvir suppresses hepatitis C with or without ribavirin Liz Highleyman / 17 June 2013 An all-oral regimen consisting of simeprevir (formerly TMC435) plus sofosbuvir, (formerly GS-7977), with or without ribavirin, produced an 8-week post-treatment sustained response for most prior null responders with genotype 1 hepatitis C in ... Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care Liz Highleyman / 29 April 2013 An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C (HCV) patients who did not respond to interferon-based triple therapy using the approved HCV protease inhibitors ... Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower Liz Highleyman / 26 April 2013 A dual oral regimen containing the hepatitis C nucleotide polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological rates overall, but this was driven by very good response amongst people with HCV genotype ... Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin Liz Highleyman / 12 March 2013 An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C studied in the phase 2a COSMOS ... Is a simple sofosbuvir plus ribavirin regimen suitable for difficult-to-treat hepatitis C patients? Liz Highleyman / 12 December 2012 An all-oral dual regimen of sofosbuvir (GS-7977) plus full-dose ribavirin was well-tolerated and produced four-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C patients in an inner-city pilot ... Telaprevir and VX-222 pair well in interferon-free regimen, VX-135 on the horizon Liz Highleyman / 03 December 2012 An all-oral regimen of telaprevir, VX-222 and ribavirin for 12 weeks was generally well-tolerated and produced sustained virological response in approximately 70% of previously untreated chronic hepatitis C patients, according to findings from ... Sofosbuvir and daclatasvir dual regimen cures most people with HCV genotypes 1, 2, or 3 Liz Highleyman / 21 November 2012 A 12-week, once-daily regimen of the hepatitis C (HCV) polymerase inhibitor sofosbuvir and the NS5A inhibitor daclatasvir, without interferon or ribavirin, produced sustained virological response rates for treatment-naive people in the 90 to 100% range, ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive